On February 15-16, FLH Partner Brian J. Malkin will attend Leerink Swann‘s 2012 Global Healthcare Conference in New York City. This year’s Conference features a Keynote Address by FDA’s Director of the Center for Drug Evaluation and Research (“CDER”) Janet Woodcock, M.D., entitled “New Trends in Drug Regulations and Innovation” as well as a panel presentation on biosimilars entitled “Biosimilars Take the Stage” featuring Dr. Woodcock as well as Steven Kozlowski, M.D., CDER’s Director of Office of Biotechnology Products, and Keith Own Webber, Ph.D., CDER’s Deputy Director, Office of Pharmaceutical Science, Acting Director, Office of Generic Drugs. Each year, Leerink Swann’s Conference brings together nearly two hundred company presentations as well as specialty panels to provide a unique and productive forum to navigate the investing landscape.
Founded in 1995, Leerink Swann is recognized as a leading healthcare investment bank to a broad range of institutional, life sciences, corporate, and high-net-worth clients that are positioned to shape the future of healthcare. All of its services are enhanced by the expertise of its proprietary MEDACorp network of 35,000+ physicians, researchers, and healthcare professionals providing insights into cutting edge advances in healthcare.